India, Feb. 18 -- Beta Bionics, Inc. (BBNX), a commercial-stage medical device company, announced financial results for the fourth quarter of 2025, posting a narrowed net loss and higher revenue compared to the prior year. However, for the full year of 2025, the net loss widened despite revenue growth.
In addition, the firm issued revenue guidance for full-year 2026.
For the fourth quarter of 2025, net loss shrank to $13.47 million from $18.11 million in the prior year. On a per-share basis, loss narrowed to $0.30 from $2.72 in the last year.
Adjusted EBITDA loss shrank to $10.51 million from $11.25 million in the year-ago period.
Revenue for the fourth quarter of 2025 increased 57% to $32.12 million from $20.44 million in the prior yea...